Good reminder that we are expecting in vivo data in H2 2023 for ALA-101 & Imugene’s onCARlytics to explore potential in solid tumors, market should keep ramping up until the release of the results. If the results are good we should see a gap up.
Ann: Investor Presentation, page-2
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ALA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.8¢ |
Change
0.008(4.17%) |
Mkt cap ! $198.0M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 19.0¢ | 17.5¢ | $130.7K | 709.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 473358 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 554679 | 7 |
View Market Depth
| Last trade - 15.48pm 01/11/2024 (20 minute delay) ? |
| ALA (ASX) Chart |